Immix Biopharma, Inc. IMMX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Immix Biopharma, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s return on equity?
- Immix Biopharma, Inc. (IMMX) reported return on equity of -74.4% in Q1 2026.
- How has Immix Biopharma, Inc.'s return on equity changed year-over-year?
- Immix Biopharma, Inc.'s return on equity increased by 33.2% year-over-year, from -111.4% to -74.4%.
- What is the long-term trend for Immix Biopharma, Inc.'s return on equity?
- Over 3 years (2022 to 2025), Immix Biopharma, Inc.'s return on equity has grown at a 1.3% compound annual growth rate (CAGR), from -52.8% to -54.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.